New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial
A two-7 days program of antiviral therapy with interferon beta-1b, plus lopinavir-ritonavir and ribavirin, started
shows
COVID-19 survey shows 85% of primary care practices lack personal protection equipment and tests
A new survey has observed that 46% of primary treatment physician methods have no potential